Thrivent Financial For Lutherans raised its position in PAREXEL International Corporation (NASDAQ:PRXL) by 6.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 10,240 shares of the medical research company’s stock after purchasing an additional 650 shares during the period. Thrivent Financial For Lutherans’ holdings in PAREXEL International Corporation were worth $890,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. NINE MASTS CAPITAL Ltd acquired a new stake in PAREXEL International Corporation in the second quarter valued at $12,455,000. BT Investment Management Ltd acquired a new stake in PAREXEL International Corporation in the second quarter valued at $314,000. Amalgamated Bank grew its holdings in PAREXEL International Corporation by 0.6% in the second quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock valued at $631,000 after purchasing an additional 42 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in PAREXEL International Corporation by 43.2% in the second quarter. Ameriprise Financial Inc. now owns 370,138 shares of the medical research company’s stock valued at $32,169,000 after purchasing an additional 111,691 shares during the last quarter. Finally, Alpine Associates Management Inc. acquired a new stake in PAREXEL International Corporation in the second quarter valued at $113,716,000. 87.45% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Thrivent Financial For Lutherans Boosts Holdings in PAREXEL International Corporation (PRXL)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/09/thrivent-financial-for-lutherans-boosts-holdings-in-parexel-international-corporation-prxl.html.

Shares of PAREXEL International Corporation (PRXL) opened at 88.08 on Monday. The stock has a 50 day moving average price of $87.85 and a 200 day moving average price of $79.27. The stock has a market capitalization of $4.50 billion, a P/E ratio of 42.76 and a beta of 0.77. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $88.10.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.08. The business had revenue of $557.20 million for the quarter, compared to analysts’ expectations of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same period in the previous year, the firm posted $0.94 EPS. On average, analysts anticipate that PAREXEL International Corporation will post $4.06 EPS for the current fiscal year.

Several research firms have weighed in on PRXL. Zacks Investment Research lowered PAREXEL International Corporation from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 target price on the stock. in a report on Tuesday, June 20th. Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Jefferies Group LLC reissued a “hold” rating and issued a $88.10 target price on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Finally, BidaskClub lowered PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $75.92.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.